Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Wednesday morning, Digital Look reports.

Other equities analysts also recently issued research reports about the stock. Credit Suisse Group set a GBX 7,300 ($95.39) price target on shares of AstraZeneca and gave the company a buy rating in a report on Friday, July 26th. Liberum Capital reiterated a hold rating and issued a GBX 6,400 ($83.63) price target on shares of AstraZeneca in a report on Wednesday, August 28th. Citigroup restated a buy rating and set a £100 ($130.67) target price (up from GBX 7,000 ($91.47)) on shares of AstraZeneca in a report on Wednesday, September 11th. Bank of America set a GBX 8,500 ($111.07) target price on shares of AstraZeneca and gave the company a buy rating in a report on Friday, September 13th. Finally, Bryan, Garnier & Co restated a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of GBX 7,050 ($92.12).

Shares of AZN opened at GBX 7,167 ($93.65) on Wednesday. The company has a 50-day simple moving average of GBX 7,191.39 and a 200-day simple moving average of GBX 6,415.44. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The company has a market capitalization of $94.02 billion and a PE ratio of 41.86. AstraZeneca has a 52-week low of GBX 5,312 ($69.41) and a 52-week high of GBX 7,583 ($99.09).

The firm also recently announced a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were issued a dividend of GBX 71.90 ($0.94) per share. The ex-dividend date was Thursday, August 8th. This represents a yield of 1.07%. AstraZeneca’s dividend payout ratio (DPR) is currently 1.28%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: What causes a yield curve to invert?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.